<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00014183</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068512</org_study_id>
    <secondary_id>MSGCC-0044</secondary_id>
    <secondary_id>NCI-1639</secondary_id>
    <nct_id>NCT00014183</nct_id>
  </id_info>
  <brief_title>ZD 1839 in Treating Patients With Stage IV or Recurrent Kidney Cancer</brief_title>
  <official_title>A Phase II Study Of ZD1839 (NSC #715055) In Renal Cell Carcinoma Stage IV And Renal Cell Carcinoma Recurrent</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Maryland Greenebaum Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <brief_summary>
    <textblock>
      RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of the tumor&#xD;
      cells and slow the growth of kidney cancer.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of ZD 1839 in treating patients who have&#xD;
      recurrent or stage IV kidney cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the response rate in patients with progressive stage IV or recurrent renal&#xD;
           cell cancer treated with ZD 1839.&#xD;
&#xD;
        -  Determine the median time to objective progression in these patients receiving this&#xD;
           drug.&#xD;
&#xD;
        -  Determine the toxic effects of this drug in this patient population.&#xD;
&#xD;
        -  Determine if epidermal growth factor receptor expression in tumor tissue correlates with&#xD;
           response and survival of these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive oral ZD 1839 daily. Courses repeat every 28 days in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 8 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 21-45 patients will be accrued for this study within 11-23&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2001</start_date>
  <completion_date type="Actual">August 2005</completion_date>
  <primary_completion_date type="Actual">May 2002</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Kidney Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gefitinib</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed stage IV or recurrent renal cell carcinoma&#xD;
             not amenable to potentially curative surgery&#xD;
&#xD;
          -  Evidence of disease progression&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  At least 20 mm with conventional techniques OR&#xD;
&#xD;
               -  At least 10 mm with spiral CT scan&#xD;
&#xD;
          -  No brain metastases&#xD;
&#xD;
          -  Malignant tissue available&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2 OR&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  More than 2 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  AST/ALT no greater than 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No prior allergy to compounds of similar chemical or biologic composition to ZD 1839&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No other uncontrolled illness or psychiatric condition that would preclude study&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No more than 2 prior immunotherapy (interferon alfa or interleukin-2) regimens&#xD;
&#xD;
          -  At least 4 weeks since prior immunotherapy and recovered&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No more than 1 prior chemotherapy regimen&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and&#xD;
             recovered&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No prior therapy for metastatic disease&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No concurrent oral retinoids&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nancy A. Dawson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Maryland Greenebaum Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Marlene &amp; Stewart Greenebaum Cancer Center, University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>April 10, 2001</study_first_submitted>
  <study_first_submitted_qc>December 31, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2004</study_first_posted>
  <last_update_submitted>November 5, 2019</last_update_submitted>
  <last_update_submitted_qc>November 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV renal cell cancer</keyword>
  <keyword>recurrent renal cell cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

